Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen in Cystic Fibrosis Patients Not Eligible for CFTR Modulators
2024-519657-11-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in cystic fibrosis (CF), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Safety and tolerability (primary). Planned start Dec 2025; status: authorised.
02
Drugs
tamoxifen
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2024-519657-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519657-11-00.